Skip to main content

Table 2 Patient demographics at baseline and characteristics during the study run-in period by poly-C repeat genotypes

From: Effect of β2-adrenergic receptor gene (ADRB2) 3′ untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response

Poly-C genotype

10a/11a

10a/12a

11a/11a

10a/13b

11a/12a

11a/13b

12a/12a

11a/14b

12a/13b

12a/14b

13b/13b

13b/14b

Genotypes <1%

Undetermined

Patients, n (%)

44 (2)

57 (3)

225 (10)

62 (3)

314 (14)

418 (19)

136 (6)

74 (3)

357 (16)

77 (3)

211 (9)

119 (5)

98 (4)

58 (3)

Ethnic origin, n (%)

              

Whitea

39 (2)

33 (2)

204 (12)

32 (2)

277 (17)

349 (21)

86 (5)

59 (4)

212 (13)

53 (3)

141 (9)

72 (4)

51 (3)

26 (2)

Black

2 (10)

0

1 (5)

4 (19)

0

1 (5)

0

0

2 (10)

0

2 (10)

2 (10)

5 (24)

2 (10)

Asian

0

12 (8)

0

15 (10)

4 (3)

3 (2)

11 (7)

0

48 (31)

8 (5)

21 (13)

15 (10)

18 (12)

1 (1)

Other

3 (1)

12 (3)

20 (5)

11 (3)

33 (8)

65 (15)

39 (9)

15 (3)

95 (22)

16 (4)

47 (11)

30 (7)

24 (5)

29 (7)

Men, n (%)

17 (1)

25 (1)

98 (4)

28 (1)

134 (6)

183 (8)

52 (2)

37 (2)

132 (6)

29 (1)

78 (3)

45 (2)

53 (2)

20 (1)

Age, mean (SD), years

39.9

(15.4)

36.1

(15.8)

39.9

(15.9)

34.8

(16.5)

39.5

(16.7)

39.1

(17.4)

36.5

(16.7)

38.6

(17.0)

37.3

(17.1)

35.2

(16.8)

35.9

(15.8)

39.0

(16.8)

34.5

(16.3)

35.6

(17.1)

FEV1, mean (SD), L

2.2

(0.6)

2.2

(0.6)

2.3

(0.6)

2.2

(0.7)

2.3

(0.7)

2.3

(0.7)

2.2

(0.6)

2.3

(0.7)

2.2

(0.7)

2.3

(0.6)

2.2

(0.7)

2.1

(0.8)

2.2

(0.7)

2.1

(0.6)

FEV1, mean (SD), % predicted

73.6

(14.3)

72.3

(12.3)

73.4

(13.4)

70.9

(13.4)

73.7

(14.1)

73.1

(12.9)

72.7

(12.6)

73.5

(11.5)

72.5

(13.5)

74.2

(13.1)

72.3

(13.9)

73.1

(16.0)

69.5

(12.8)

70.7

(13.5)

FEV1 reversibility, mean (SD), %

25.6

(16.4)

24.2

(11.6)

23.6

(12.9)

22.2

(11.0)

24.4

(12.3)

24.0

(12.2)

25.4

(12.6)

24.5

(12.9)

25.6

(14.3)

26.4

(16.6)

24.7

(11.7)

22.9

(10.8)

24.1

(13.9)

26.5

(12.8)

FVC, mean (SD), L

2.9

(0.7)

3.0

(0.8)

3.2

(1.0)

2.9

(0.9)

3.2

(1.0)

3.1

(0.9)

3.0

(0.9)

3.1

(0.9)

2.9

(1.0)

3.0

(0.9)

3.0

(1.0)

2.9

(0.9)

3.0

(1.0)

2.8

(0.7)

ICS dose at study entry, mean (SD), μg per day

747.7

(261.9)

750.0

(195.5)

766.0

(249.6)

796.0

(232.6)

734.1

(216.4)

749.0

(243.6)

701.8

(207.0)

776.4

(239.0)

708.0

(221.5)

734.4

(254.7)

745.3

(250.5)

694.5

(189.3)

713.8

(191.9)

736.2

(236.0)

Morning PEF during run-in, mean (SD), L/min

322.1

(88.7)

331.4

(103.5)

341.6

(98.1)

338.4

(99.6)

340.7

(92.7)

334.9

(99.0)

337.8

(82.3)

350.5

(95.1)

321.6

(92.0)

342.2

(90.6)

333.1

(85.6)

320.3

(98.3)

358.7

(106.8)

316.5

(76.7)

Total rescue medication use during run-in, mean (SD), inhalations/day

2.2

(1.1)

2.5

(1.6)

2.5

(1.6)

2.5

(1.4)

2.3

(1.4)

2.4

(1.5)

2.2

(1.5)

2.4

(1.4)

2.2

(1.2)

2.1

(1.1)

2.3

(1.2)

2.4

(1.3)

2.2

(1.3)

3.1

(2.2)

Nights with awakenings during run-in, mean (SD), %

32.6

(35.9)

33.8

(33.8)

31.8

(34.6)

33.5

(33.7)

35.7

(35.0)

32.2

(34.0)

33.5

(35.5)

34.5

(37.0)

33.4

(35.1)

35.7

(36.9)

33.7

(35.8)

29.8

(35.1)

32.9

(36.7)

47.1

(35.6)

Total symptom score, mean (SD)

1.9

(0.7)

2.0

(0.9)

1.9

(0.9)

1.9

(0.9)

2.0

(0.9)

2.0

(0.9)

1.9

(1.0)

2.0

(0.9)

1.9

(0.9)

1.8

(0.7)

2.0

(0.9)

2.1

(1.0)

1.9

(1.0)

2.2

(1.1)

  1. aWhites of European descent.
  2. Baseline and run-in characteristics for patients of all races. Genotypes present at a frequency of <1% are grouped together, and patients whose poly-C genotype was undetermined are grouped together. FEV 1 = forced expiratory volume in one second; FVC = forced vital capacity; ICS = inhaled corticosteroid; PEF = peak expiratory flow; SD = standard deviation.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us